Pamorelin

Pamorelin

triptorelin

Manufacturer:

UNILAB, Inc

Distributor:

UNILAB, Inc
Concise Prescribing Info
Contents
Triptorelin embonate
Indications/Uses
Palliative treatment of locally advanced non-metastatic & metastatic hormone-dependent prostate cancer, as an alternative to surgical castration. Adjuvant treatment to radiotherapy in patients w/ high risk localized or locally advanced prostate cancer. Treatment of endometriosis (3.75 mg only).
Dosage/Direction for Use
Prostate cancer 3.75 mg inj 1 IM inj or 1 SC inj every mth. 11.25 mg inj 1 IM inj every 3 mth. 22.5 mg inj 1 IM inj every 6 mth. Endometriosis 3.75 mg inj Single IM or SC inj every 28 days, to be initiated in the 1st 5 days of the menstrual cycle. Max duration of treatment: 6 mth.
Contraindications
Hypersensitivity to triptorelin, GnRH, GnRH agonists analogs. Women w/ undiagnosed abnormal vag bleeding. Pregnancy & lactation.
Special Precautions
Transient increase in serum testosterone levels. Bone mineral density loss. Increased risk of developing hyperglycemia & diabetes. Monitor blood glucose &/or HbA1c periodically. Suppression of pituitary gonadotropins & gonadal hormone. Discontinue use if anaphylactic shock, hypersensitivity & angioedema occurs. Increased neurologic &/or genitourinary complications. May increase risk of CV diseases (eg, MI, sudden cardiac death & stroke). Potential QT/QTc interval prolongation. Risk of anemia. Pituitary apoplexy. Monitor patients w/ known depression; serum levels of testosterone & prostate specific antigen periodically. Vag bleeding; ovarian cysts. Renal & hepatic impairment. May impair ability to drive or operate machinery. Childn <18 yr. Elderly >65 yr.
Adverse Reactions
Men: Induced variation in serum testosterone levels. Women: Hot flushes, vag dryness, amenorrhea. Allergic reactions. Local, CV, nervous, endocrine, GI & hepatic, musculoskeletal, resp, dermatologic, genitourinary, sensory effects. Asthenia, fatigue & bruising.
Drug Interactions
Concomitant use w/ drugs affecting pituitary secretion of gonadotropins. Diagnostic tests of the pituitary-gonadal function conducted during treatment & w/in 4-12 wk after cessation of therapy may be misleading.
ATC Classification
L02AE04 - triptorelin ; Belongs to the class of gonadotropin releasing hormone analogues. Used in endocrine therapy.
Presentation/Packing
Form
Pamorelin lyophilized powd for inj 3.75 mg
Packing/Price
1's
Form
Pamorelin lyophilized powd for inj 22.5 mg
Packing/Price
1's
Form
Pamorelin lyophilized powd for inj 11.25 mg
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in